FDA ques­tions Zevra’s re­sub­mit­ted da­ta for rare dis­ease drug ahead of ad­comm

Ahead of an ad­vi­so­ry meet­ing Fri­day, the FDA raised ques­tions about the strength of hu­man, mouse and cell da­ta Zevra Ther­a­peu­tics gen­er­at­ed for its treat­ment …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER